Physician profile
Kiesha Harris
NPI 1780262014
$653.85
in general payments reported to CMS, 2019-2025
14 companies · $246 in 2025
The $246 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $41.61 · 2023: $48.08 · 2024: $318 · 2025: $246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $612.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $612.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $135.24 | 2024 | Biktarvy |
| Harmony Biosciences LLC | $112.29 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $86.57 | 2024-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $49.54 | 2022-2024 | Fanapt, Hetlioz |
| Novo Nordisk INC | $44.07 | 2023-2024 | Rybelsus, Wegovy |
| Abbvie INC. | $35.05 | 2023-2025 | |
| Tris Pharma INC | $34.46 | 2025 | Dyanavel Xr |
| Dexcom, INC. | $25.70 | 2024 | Dexcom G6 Transmitter |
| Alkermes, INC. | $25.55 | 2025 | Aristada, Lybalvi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.19 | 2022 | |
| Lundbeck LLC | $24.34 | 2025 | Rexulti |
| Astellas Pharma US INC | $24.22 | 2025 | Veozah |
| Teva Pharmaceuticals USA, INC. | $15.82 | 2025 | Uzedy |
| Indivior INC. | $15.81 | 2023 | Perseris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kiesha Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.